Complement Activation in the Treatment of B-Cell Malignancies

Antibodies

JonathanJ. Pinney¹  MichaelR. Elliott¹  CharlesC. Chu²  CliveS. Zent² 

[1] Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA;Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA;

关键词: complement;    cytotoxicity;    phagocytosis;    monoclonal antibody;    B-cell lymphoma;    chronic lymphocytic leukemia (CLL);   

DOI  :  10.3390/antib9040068

来源: DOAJ

【 摘 要 】

Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-dependent cytotoxicity (CDC) and complement receptor-mediated antibody-dependent cellular phagocytosis (cADCP). Clinical and laboratory studies have showed that CDC is therapeutically important. In contrast, the biological role and clinical effects of cADCP are less well understood. This review summarizes the available data on the role of complement activation in the treatment of mature B-cell malignancies and proposes future research directions that could be useful in optimizing the efficacy of this important class of drugs.

【 授权许可】

Unknown